American Portfolios Advisors Vericel Corp Transaction History

American Portfolios Advisors

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Mar 20, 2023	BUY	$22.88 - $39.45 $1,395 - $2,406	61 New	61 $1.54 Million
Q1 2022 Mar 21, 2023	BUY	$31.69 - $43.29 $1,933 - $2,640	61 New	61 $2.33 Million
Q4 2021 Mar 21, 2023	BUY	$35.2 - $52.6 $2,288 - $3,419	65 New	65 $2.56 Million
Q3 2021 Mar 22, 2023	BUY	$46.35 - $59.75 $117,960 - $152,063	2,545 New	2,545 $124 Million
Q2 2021 Mar 22, 2023	BUY	$47.2 - $67.81 $118,188 - $169,796	2,504 New	2,504 $131 Million
Q1 2021 Mar 22, 2023	BUY	$30.93 - $59.48 $77,448 - $148,937	2,504 New	2,504 $139 Million
Q4 2020 Mar 22, 2023	BUY	$18.53 - $31.5 $46,399 - $78,876	2,504 New	2,504 $77.3 Million
Q3 2020 Mar 22, 2023	BUY	$14.68 - $19.12 $205 - $267	14 New	14 $259,000
Q2 2019 Mar 24, 2023	BUY	$15.01 - $18.89 $4,503 - $5,667	300 New	300 $5.67 Million

277

48.4M

91.8K

23.2K

Ticker VCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,178,000
Market Cap $2.6B
Description
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for t...

Get notified when there are updates to the investment portfolio of American Portfolios Advisors, based on Form 13F filings with the SEC.

Stay updated on American Portfolios Advisors with notifications on news.